Iovance's revenue rose 66% last quarter due to strong demand for Amtagvi. The company also cut its l

Iovance rises 43% after Q2 results top estimates as Amtagvi sales beat forecasts, boosting revenues

The mean of analysts' price targets for Iovance Biotherapeutics (IOVA) points to a 28% upside in the

Iovance Biotherapeutics NASDAQ: IOVA reported record second-quarter revenue and gross margin, driven

Iovance Biotherapeutics is rated a buy, driven by strong Q2 results, surging Amtagvi sales, and prom

Iovance Biotherapeutics, Inc. (IOVA) Q2 2026 Earnings Call Transcript

Gainers Creative Medical Tech (NASDAQ:CELZ) stock increased by 107.8% to $1.39 during Thursday'

Iovance Biotherapeutics (IOVA) came out with a quarterly loss of $0.11 per share versus the Zacks Co

US stocks mixed on Thurs. Dow Jones down 50 pts. Motorola Solutions Inc shares up 9.5% after reporti

Gainers Creative Medical Tech (NASDAQ:CELZ) stock increased by 86.9% to $1.25 during Thursday's

U.S. Amtagvi Revenue Reaches ~$91M and Total Revenue Increased 66% Year-over-Year Gross Margin Incre

SAN CARLOS, Calif., July 30, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA),

This whale alert can help traders discover the next big trading opportunities. Whales are entities w

SAN CARLOS, Calif., July 17, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) (

Iovance Biotherapeutics is showing steady operational and financial progress, supporting a speculati

The biotech is clearly innovative, but sometimes that's not enough.

Heartflow leverages AI-enabled software to dominate the non-invasive coronary diagnostic market, bac

Amgen provides a stable, diversified revenue base of nearly $36.7 billion with significant net incom

SAN CARLOS, Calif., June 19, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) (

IOVA guides for $350M–$370M 2026 revenue (36% YoY growth), with Q2'26 expected to be a record Amtagv

First T cell therapy for a solid tumor cancer and first treatment option approved in Australia for a

Iovance Biotherapeutics has surged over the past year, but the stock is down by nearly 80% over the

Iovance Biotherapeutics (NASDAQ:IOVA) said it has obtained clearance of an Investigational New Drug

Iovance Biotherapeutics (NASDAQ:IOVA) said it has obtained clearance of an Investigational New Drug

U.S. stock futures fall 250 points, Highpeak Energy shares drop 7%. Other stocks also down in pre-ma

U.S. stock futures fall 250 points, Highpeak Energy shares drop 7%. Other stocks also down in pre-ma

Companies Reporting Before The Bell • ICL Group (NYSE:ICL) is likely to report quarterly earnings a

Shares of International Flavors & Fragrances Inc. (NYSE: IFF) fell during Wednesday’s session a

Companies Reporting Before The Bell • CorEnergy Infr Tr (NYSE:CORR) is estimated to report earnings

  On Thursday, 369 companies hit new 52-week lows.

  On Wednesday, 311 stocks hit new 52-week lows.

  On Tuesday, 647 companies set new 52-week lows.